HORMONE REPLACEMENT THERAPY AND CANCER
<p>Background. Sex steroids are not known to damage DNA directly. They can stimulate or inhibit cell proliferation, and thus can modulate tumor developmental progression.</p><p>Results. Sex steroids-related tumors in women are represented by breast cancer and endometrial cancer, an...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Slovenian Medical Association
2003-12-01
|
| Series: | Zdravniški Vestnik |
| Subjects: | |
| Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/1956 |
| _version_ | 1811343956651278336 |
|---|---|
| author | Marjetka Uršič Vrščaj |
| author_facet | Marjetka Uršič Vrščaj |
| author_sort | Marjetka Uršič Vrščaj |
| collection | DOAJ |
| description | <p>Background. Sex steroids are not known to damage DNA directly. They can stimulate or inhibit cell proliferation, and thus can modulate tumor developmental progression.</p><p>Results. Sex steroids-related tumors in women are represented by breast cancer and endometrial cancer, and a possible relationship exists between sex steroids and both ovarian and colon cancer. Among current ERT users or those who stopped use 1–4 years previously, the relative risk of having breast cancer diagnosed is low, increases by factor of 1.023 for each year of hormone use. An appropriate combination of estrogen and progestin does not appear to increase, and may even decrease, the risk of endometrial cancer. Studies on HRT and risk of epithelial ovarian cancer have produced conflicting results but most data seem to exclude a strong assotiation. It is important that available data suggest a reduced risk of benign colorectal adenoma and colon cancer for 30–40%.</p><p>Conclusions. After breast cancer, endometrial cancer, melanoma or epithelial ovarian cancer HRT is not absolute contraindication. Low-grade endometrial stromal sarcoma should be considered to be a contraindication to HRT.<br /><br /></p> |
| first_indexed | 2024-04-13T19:39:11Z |
| format | Article |
| id | doaj.art-d1fb25fe12e34aa183690005621bbe11 |
| institution | Directory Open Access Journal |
| issn | 1318-0347 1581-0224 |
| language | English |
| last_indexed | 2024-04-13T19:39:11Z |
| publishDate | 2003-12-01 |
| publisher | Slovenian Medical Association |
| record_format | Article |
| series | Zdravniški Vestnik |
| spelling | doaj.art-d1fb25fe12e34aa183690005621bbe112022-12-22T02:32:56ZengSlovenian Medical AssociationZdravniški Vestnik1318-03471581-02242003-12-017201452HORMONE REPLACEMENT THERAPY AND CANCERMarjetka Uršič Vrščaj0Onkološki inštitut Zaloška 2 1000 Ljubljana<p>Background. Sex steroids are not known to damage DNA directly. They can stimulate or inhibit cell proliferation, and thus can modulate tumor developmental progression.</p><p>Results. Sex steroids-related tumors in women are represented by breast cancer and endometrial cancer, and a possible relationship exists between sex steroids and both ovarian and colon cancer. Among current ERT users or those who stopped use 1–4 years previously, the relative risk of having breast cancer diagnosed is low, increases by factor of 1.023 for each year of hormone use. An appropriate combination of estrogen and progestin does not appear to increase, and may even decrease, the risk of endometrial cancer. Studies on HRT and risk of epithelial ovarian cancer have produced conflicting results but most data seem to exclude a strong assotiation. It is important that available data suggest a reduced risk of benign colorectal adenoma and colon cancer for 30–40%.</p><p>Conclusions. After breast cancer, endometrial cancer, melanoma or epithelial ovarian cancer HRT is not absolute contraindication. Low-grade endometrial stromal sarcoma should be considered to be a contraindication to HRT.<br /><br /></p>http://vestnik.szd.si/index.php/ZdravVest/article/view/1956estrogensreceptorsoncogene proteinscancer recurrencemenopauseselective estrogen receptors modulators |
| spellingShingle | Marjetka Uršič Vrščaj HORMONE REPLACEMENT THERAPY AND CANCER Zdravniški Vestnik estrogens receptors oncogene proteins cancer recurrence menopause selective estrogen receptors modulators |
| title | HORMONE REPLACEMENT THERAPY AND CANCER |
| title_full | HORMONE REPLACEMENT THERAPY AND CANCER |
| title_fullStr | HORMONE REPLACEMENT THERAPY AND CANCER |
| title_full_unstemmed | HORMONE REPLACEMENT THERAPY AND CANCER |
| title_short | HORMONE REPLACEMENT THERAPY AND CANCER |
| title_sort | hormone replacement therapy and cancer |
| topic | estrogens receptors oncogene proteins cancer recurrence menopause selective estrogen receptors modulators |
| url | http://vestnik.szd.si/index.php/ZdravVest/article/view/1956 |
| work_keys_str_mv | AT marjetkaursicvrscaj hormonereplacementtherapyandcancer |